Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19087 ↗At a glance
Journal article in British Journal of Haematology, 2024. Written by Yandong Shen and 6 co-authors. Institution: Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia. Major MEDLINE topics: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphocytosis, COVID-19, Vaccines. Cited 3 times so far (Crossref); 15 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
We analysed COVID‐19 infection outcomes of 129/241 chronic lymphocytic leukaemia (CLL) (53.9%) and 22/55 monoclonal B‐lymphocytosis (MBL) (40.0%) patients following multiple vaccine doses aiming for maximum measured anti‐spike antibody response. Throughout the pandemic to date, there were 8/129 CLL (6.2%) patients hospitalised, with one death (0.8%). No MBL patients were hospitalised or died. CLL patients with COVID‐19 had lower anti‐spike levels (3778.8 AU/mL) than those without (13 486.8 AU/mL; p = 0.0061). Anti‐nucleocapsid antibody was detected in 29.8% within 2 months and 17.5% >6 months. Of COVID‐19‐infected CLL patients, 47.3% received anti‐viral therapy. A multiple vaccine dosing strategy to achieve measured maximum antibody is highly effective in preventing severe COVID‐19.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
- Kolling Institute, Royal North Shore Hospital, University of Sydney, St Leonards, New South Wales, Australia.
- Department of Haematology and Flow Cytometry, Healius Laverty Pathology, Macquarie Park, New South Wales, Australia.
- Northern Haematology and Oncology Group, Sydney Adventist Hospital, Wahroonga, New South Wales, Australia.
- Department of Microbiology, Healius Laverty Pathology, Macquarie Park, New South Wales, Australia.
ORCID profiles: Yandong Shen, Jane A Freeman, Ian Kerridge, Stephen P Mulligan
Cite
APA
Shen, Y., Freeman, J. A., Kerridge, I., Downe, P., Naidu, K., Holland, J., & Mulligan, S. P. (2024). Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL. British Journal of Haematology. https://doi.org/10.1111/bjh.19087
Vancouver
Shen Y, Freeman JA, Kerridge I, Downe P, Naidu K, Holland J, et al. Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL. British Journal of Haematology. 2024. doi:10.1111/bjh.19087
BibTeX
@article{Shen2024,
author = {Shen, Yandong and Freeman, Jane A and Kerridge, Ian and Downe, Paul and Naidu, Kartik and Holland, Juliette and Mulligan, Stephen P},
title = {Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19087}
}
EUVIMED